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Pyrazinamide (PZA) is an antibiotic used in first- and second-line tuberculosis treatment regimens. 
Approximately 50% of multidrug-resistant tuberculosis and over 90% of extensively drug-resistant 
tuberculosis strains are also PZA resistant. Despite the key role played by PZA, its mechanisms of action 
are not yet fully understood. It has been postulated that pyrazinoic acid (POA), the hydrolyzed product 
of PZA, could inhibit trans-translation by binding to Ribosomal protein S1 (RpsA) and competing with 
tmRNA, the natural cofactor of RpsA. Subsequent data, however, indicate that these early findings 
resulted from experimental artifact. Hence, in this study we assess the capacity of POA to compete 
with tmRNA for RpsA. We evaluated RpsA wild type (WT), RpsA ∆A438, and RpsA ∆A438 variants with 
truncations towards the carboxy terminal end. Interactions were measured using Nuclear Magnetic 
Resonance spectroscopy (NMR), Isothermal Titration Calorimetry (ITC), Microscale Thermophoresis 
(MST), and Electrophoretic Mobility Shift Assay (EMSA). We found no measurable binding between POA 
and RpsA (WT or variants). This suggests that RpsA may not be involved in the mechanism of action of 
PZA in Mycobacterium tuberculosis, as previously thought. Interactions observed between tmRNA and 
RpsA WT, RpsA ∆A438, and each of the truncated variants of RpsA ∆A438, are reported.
Tuberculosis (TB), caused by Mycobacterium tuberculosis (MTB), is responsible for 1.4 million deaths and 10.4 
million new cases of disease each year1.
Depending on various factors, including the immune response of the host2, MTB may either cause latent 
infection or active disease. It is estimated that latent infection affects one quarter of the population worldwide 
who do not have clinical manifestations of the disease but have an estimated 2.4–10% lifetime risk of activation 
and development of active TB3,4.
Pyrazinamide (PZA) is an anti-tuberculosis antibiotic used in first- and second-line regimens. It reduces 
the treatment period from nine to six months and diminishes the risk of relapse due to its activity against 
semi-dormant mycobacteria5. PZA is a pro-drug that enters the bacteria by passive diffusion and hydrolyzes to its 
active form, pyrazinoic acid (POA)6.
The POA is then expelled out of the mycobacterium by an efflux mechanism. If the pH of the extracellu-
lar environment is acidic, the POA is protonated to POAH, re-enters the cell, and the proton is released in the 
cytosol. This cycle repeats itself, causing an intra-cellular accumulation of POA and a reduction in the pH of the 
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cytoplasm. This leads to a lethal alteration of membrane permeability; however, the exact mechanism by which 
this occurs is not yet known7 It is important to remark, that other recent studies, found that extracellular acid pH 
is not required to have PZA/POA achieve its lethal effect8–10. This confirms that the real mechanism of action of 
PZA is actually more complicated than though, and significant further research is required.
It has been demonstrated that the anti-bacterial properties of PZA could be associated with various mech-
anisms of action, including the alteration of membrane energy production7, inhibition of trans-translation11,12, 
inhibition of pantothenate and CoA biosynthesis13, and inhibition of Fatty Acid synthetase (FAS I)14.
RpsA is a ribosomal protein that has been extensively studied in Escherichia coli (E. coli). Its main functions 
include: participation in the initiation of translation15,16; the recognition of messenger RNA (mRNA) bearing 
weak or degenerated Shine-Dalgarno sequences17,18; and participation in trans-translation19.
During protein biosynthesis the ribosome can be stalled by an mRNA which has lost its stop codon, by oth-
erwise defective mRNA, or in the absence of tRNA during translation20. Trans-translation is a system in which 
transfer-messenger RNA (tmRNA), which is encoded by the ssrA gene, interacts with Small protein B (SmpB)21, 
elongation factor Tu (EF-Tu)22, and RpsA19,23 to form a ribonucleoprotein complex that efficiently releases the 
stalled ribosome.
In mycobacteria, studies investigating trans-translation have shown that exposure to ribosome-targeting 
antibiotics results in the upregulation of tmRNA expression, although the mechanism through which this 
takes place remains unknown22. It has been suggested that POA interacts with RpsA, and by doing so inhibit 
trans-translation, with lethal consequences for metabolically dormant mycobacteria11. In contrast, Personne 
and Parish24 claim that PZA may not directly affect trans-translation in MTB, because SmpB deletions and ssrA 
gene mutations did not generate noticeable changes to the bacterial growth pattern. Furthermore, Yang et al.12 
crystallized the fourth domain of MTB RpsA with and without POA. The residues Phe307, Phe310, His322 and 
Arg357 were found to interact with POA, as well as with tmRNA12. PZA-resistant clinical strain, DHM 444, 
was reported11 to harbor an alanine deletion at position 438 (∆Ala438) on the unstructured carboxy terminal 
(C-terminal) end of RpsA. It was suggested that this deletion blocked the interaction between POA and RpsA, 
preventing the lethal inhibition of trans-translation and resulting in resistance to PZA11.
In contrast to these findings, Dillon et al., using Isothermal Titration Calorimetry found no evidence of an 
interaction between RpsA and POA25. This study applied allelic exchange to PZA-susceptible laboratory MTB 
strain H37Ra. No significant differences were found in the PZA MICs in RpsA ∆Ala438 when compared to the 
wild type strain, and there was no inhibition of trans-translation by POA. The authors also showed that neither 
∆Ala438 nor RpsA over-expression conferred resistance to PZA, in contrast to previous reports11,26.
Based on these discrepancies, the present study evaluated the interaction between RpsA and POA, as well as 
between RpsA and tmRNA, for both the RpsA wild type (RpsA WT) and RpsA ∆A438 proteins, using a range 
of techniques including Electrophoretic Mobility Shift Assay (EMSA), Isothermal Titration Calorimetry (ITC), 
Microscale Themophoresis (MST) and Nuclear Magnetic Resonance spectroscopy (NMR).
Considering that MTB RpsA is composed of four S1 domains and a highly flexible C-terminal end27,28, two 
hypotheses were addressed in order to understand why ∆A438 deletion in RpsA protein induced resistance11. 
The first hypothesis proposed that the ∆Ala438 mutation favors movement of the non-structured C-terminal 
end of MTB RpsA, leading to blockage, by steric impediment, of the entry of POA to the MTB RpsA binding site. 
The second hypothesis postulates that the ∆Ala438 mutation induces a conformational change within the POA 
binding site, reducing its overall affinity. To evaluate these hypotheses, RpsA variants with truncated C-terminal 
regions were carefully designed (RpsA ∆Ala438_CUT1, RpsA ∆Ala438_CUT2, and RpsA ∆Ala438_CUT3) to 
limit the capacity of the non-structured end to block the POA binding site. Thereby enable POA to recover its 
ability to bind to MTB RpsA, assuming that this was lost as a result of the ∆Ala438 mutation Fig. 1.
Results
Production of RpsA. RpsA and all its variants were purified as soluble proteins. In all cases, native 5% PAGE 
and ethidium bromide stained revealed the presence of nucleic acids bound to the purified proteins. Treatment 
with DNase and RNase showed that these nucleic acids were RNA (Supplementary Figure S1).
Electrophoretic mobility shift assay (EMSA) to test the interaction between tmRNA, RpsA WT 
and RpsA ∆A438. EMSA is a simple technique based on the identification of the electrophoretic mobility 
pattern of the nucleic acid when it is free and when it forms complexes with the target protein, as in the latter case 
migration will usually be slower29. Free tmRNA showed greater electrophoretic mobility than tmRNA incubated 
in the presence of RpsA WT or RpsA ∆A438 (Fig. 2), confirming an interaction between both RpsA variants with 
tmRNA, as described previously11,12.
Microscale thermophoresis (MST) to test the interaction between tmRNA and RpsA WT. MST 
is a relatively new approach that requires few sample quantity, fast, easy and the only requirement for its use was 
to bind covalently the protein with a fluorophore30. Microscale thermophoresis was used to confirm the inter-
action between RpsA WT and tmRNA, and to determine the dissociation constant (Fig. 3). Its variability was 
calculated after data fitting and estimation of parameters, yielding a Kd value of 58.1 +/− 2.95 nM.
Electrophoretic mobility shift assay (EMSA) to test the interaction between POA and RpsA 
variants. tmRNA was able to positively bind to all RpsA variants (Fig. 4, lanes 2, 4, 6 and 8). However, dis-
placement of tmRNA at saturating concentrations of POA was not observed for any of the protein variants tested 
(RpsA WT, RpsA ∆Ala438, and the truncated variants, Fig. 4, lanes 3, 5, 7 and 9), indicating that POA does not 
compete with tmRNA for RpsA.
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Isothermal titration calorimetry (ITC) to test the interaction between POA and RpsA vari-
ants. ITC is a technique to determine the thermodynamic parameters from drug binding interactions with 
proteins in their native state, without chemical modification or adhesion to any surface31,32. We found no vari-
ation in thermodynamic parameters during ITC. Highly acidic POA generated a dilution heat signal when the 
pH of the assay was not conditioned to overcome the pH change induced by POA (Fig. 5A). When adjusted, the 
results clearly indicate no affinity between RpsA and POA for either RpsA WT, RpsA ∆A438 (Fig. 5B, 5C), or the 
truncated variants RpsA ∆Ala438_CUT1, RpsA ∆Ala438_CUT2, and RpsA ∆Ala438_CUT3 (Supplementary 
Figure S2).
Nuclear magnetic resonance spectroscopy (NMR) to test the interaction between POA and 
RpsA variants. NMR is a powerful tool used to determine molecular interactions33. One of the simplest 
methods to investigate protein–ligand interactions by NMR is to observe the Chemical Shift Perturbation (CSP) 
induced by complex formation. If the interactions are in the nanomolar or sub-nanomolar affinity range, the 
resonances are usually observed in the slow NMR exchange regime in which two signals can be observed, one 
Figure 1. Cutting scheme for the generation of truncated proteins at the C-terminal end of RpsA ∆A438.
Figure 2. Electrophoretic Mobility Shift Assay (EMSA) to evaluate interactions between tmRNA and RpsA WT 
and RpsA ∆Ala438. Lane 1: RpsA WT and tmRNA; Lane 2: tmRNA; Lane 3: RpsA ∆A438 and tmRNA.
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coming from the free ligand and the other from the ligand complex. In the case of a micromolar range affinity 
protein-ligand interaction, the signals involved are usually detected by the fast NMR exchange regime in which 
the two signals collapse into one, and the total displacement of the chemical shift depends on the equilibrium 
concentrations between the free and the bound state.
The NMR spectrum of POA is composed of downfield aromatic signals (1Hortho: 9.07 ppm, 1Hmeta and 1Hpara: 
8.7 ppm), none of which overlap with signals associated with the protein (Supplementary Figure S3). Fig. 6 shows 
the signals generated by POA against increasing concentrations of RpsA WT. No evidence of any CSP or inte-
gral diminishment of POA NMR signals was observed, even in the presence of more than three times an excess 
of RpsA WT. However, at high RpsA WT concentrations a small change in the line-width of POA signals is 
observed, indicative of a change in relaxation.
To confirm these results, we measured the diffusion coefficient of POA in the absence and presence of RpsA 
WT (7.1 × 10−10m2/s and 7.0 × 10−10m2/s, respectively; supplementary Figure S4). In the bound state, the ligand 
is expected to acquire the diffusion coefficient of the protein (1.4 × 10−10 m2/s), which would result in a lower 
apparent diffusion rate, depending on the average time spent in the bound and unbound state33,34. There was 
no reduction in the apparent diffusion coefficient, even in the presence of excess RpsA WT (supplementary 
Figure S4).
To evaluate the possibility of an affinity at the millimolar level, we performed Saturation Transfer Difference 
(STD) experiments35. This method is based on the selective saturation of the protein signals which are transferred 
to the ligand by spin diffusion. This method allows the determination of affinities in the micro- and millimolar 
range. First, we performed a series of STD experiments at low RpsA WT concentrations (1.1 μM, 3 μM and 4.5 μM). 
Figure 3. Evaluation of the interaction between RpsA WT (Red-tris-NTA) and tmRNA by Microscale 
Thermophoresis (MST). Kd= 58.1 +/− 2.95 nM. Monolith NT.115 peak.
Figure 4. Competition between tmRNA and POA for RpsA (EMSA). Lane 1: tmRNA; Lane 2–3: RpsA WT; 
Lane 4–5: RpsA ∆A438; Lane 6–7: RpsA ∆A438_CUT1: Lane 8–9: RpsA ∆A438 _CUT3. Two gels are shown 
with equal running conditions (gel 1: Lanes 1–7; gel 2: Lanes 8–9).
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No saturation transfer between RpsA WT and POA was detected (Fig. 7, Supplementary Figure S5 and S6). Next, 
high concentration (50 μM RpsA WT) STD experiments with different RpsA/POA molar ratios (1/2, 1/5, 1/7, 
1/10 and 1/20) were tested. Only marginal saturation transfer was observed (Fig. 8 and Supplementary Figures S8, 
S9, S10 and S11). This small STD signal could be explained by a weak interaction (in the mM range), which is too 
low to be detected under the conditions tested (Supplementary Figure S12). In any case, this weak interaction, 
even high concentrations of POA, is not sufficient to explain the competitive effect between POA and tmRNA 
claimed in earlier studies11.
Figure 5. Evaluation of the interaction between RpsA and RpsA ∆A438 and POA, determined by Isothermal 
Titration Calorimetry (ITC). (A,B) RpsA WT, without (A) and with (B) pH correction and (C) RpsA ∆A438.
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Figure 6. Chemical Shift Pertubation (CSP) experiment: 1H NMR spectrum of 100 μM POA with different 
concentrations of RpsA. From bottom to top: 0 μM, 6.6 μM, 13.1 μM, 26.3 μM, 52.5 μM, 157.5 μM, and 315 μM 
RpsA.
Figure 7. Saturation transfer difference (STD) experiment using 200 μM POA and 4.5 μM RpsA: (top) Off 
resonance spectrum; (middle) On resonance spectrum; (bottom) STD spectrum.
Figure 8. Saturation transfer difference (STD) experiment using 500 μM POA and 50 μM RpsA: (top) Off 
resonance spectrum; (middle) On resonance spectrum; (bottom) STD spectrum.
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Discussion
Shi et al.11 suggested that PZA may be inhibiting trans-translation or the salvage of ribosomes by dissociating the 
tmRNA-RpsA complex. In the same year, Andini and Nash22 postulated that the trans-translation mechanism 
may be vital for the survival of mycobacteria. In the study by Shi et al. (2011), the ∆Ala438 deletion located at the 
highly flexible C-terminal end of the MTB RpsA protein in a PZA-resistant clinical strain was reported, and it was 
suggested that this mutation may have been responsible for the change to a PZA resistant phenotype. Based on 
this finding, in the present study we sought to investigate and understand the effect of the ∆Ala438 deletion on 
the conserved RpsA protein36 and on its relationship with the mechanism of resistance to PZA.
Andini and Nash22 previously reported that Mycobacterium smegmatis, a naturally PZA resistant mycobac-
teria, has between 500 and 1000 copies of tmRNA per cell, a ratio of 1:10 or 1:20 tmRNA:ribosomes, similar to 
E. coli37. Assuming that this ratio is similar in MTB, according to the hypothesis presented by Shi et al. (2011) 
we would expect that POA would compete with tmRNA, saturating the sites of interaction between tmRNA and 
ribosomes, either by a high intracellular POA concentration or by having an affinity greater than that of tmRNA.
To evaluate the postulated POA/RpsA interaction and the ability of POA to displace tmRNA from RpsA we 
employed a range of experimental approaches, as well as different C-terminal truncated variants of RpsA. Our 
results consistently showed that POA does not compete with tmRNA for RpsA, since no displacement of tmRNA 
from RpsA or any of its variants was observed in the presence of excess POA. This finding contrasts with what has 
previously been reported11,12.
We found that purified MTB RpsA protein recombinant expressed in E. coli was bound to RNA 
(Supplementary Figure S1). This has also been previously observed with E. coli RpsA38. Although we took steps 
to eliminate RNA from our purified recombinant RpsA, this was not performed in the studies conducted by Shi 
et al. (2011) or by Yang et al. (2015). This omission may have led to background noise in the interaction assays 
performed in those studies, and the subsequent mis-interpretation of this noise as a positive finding. Having 
controlled for RNA contamination in the purified RpsA, we consider that our results are free of any potential 
confounding caused by it. We believe future studies are required to evaluate the consequences of potential con-
tamination with RNA of purified RpsA from M. tuberculosis and other mycobacterias as M. smegmatis.
In addition, EMSA analysis showed that both the RpsA WT and RpsA ∆Ala438 proteins were able to form 
complexes with tmRNA. Fan et al.39 approximated the binding between RpsA and tmRNA by generating a trun-
cated RpsA protein comprising residues 280–438 (only the fourth domain and the C-terminal end), and evalu-
ated its interaction with two variants of the mRNA domain of MTB tmRNA. The binding was estimated to have 
an affinity constant between 23.56 +/− 5.74 and 92.17 +/− 17.80 × 104 M−1 39, which partially characterizes the 
affinity between RpsA and tmRNA. In our study, the apparent binding constant between RpsA WT (full length 
protein and truncated variants) and MTB tmRNA was estimated at 1.72 +/− 0.873 × 107 M−1, compared to the 
1 × 108 M−1 previously reported for E. coli tmRNA40. Therefore, the positive control (RpsA-tmRNA) used in our 
interaction model is both qualitatively and quantitatively consistent with published data.
As previously reported by Dillon25, ITC measurements of RpsA WT and POA interactions generated inter-
esting results. The addition of POA (pKa 2.9) without pH adjustment to the protein solution led to an ITC sig-
nal corresponding to − 917.3 +/− 25.13 cal/mol (Fig. 5A), a value that could be misinterpreted as a molecular 
interaction. However, considering that the energy of a hydrogen bond varies from 1–40 Kcal/mol41,42, the ther-
modynamic parameters are unlikely to correspond to a specific bond between these molecules but rather to a 
dilution heat differential. When the pH was corrected (Fig. 5B), this phenomenon was no longer present and no 
interaction between RpsA WT and POA was observed. To further confirm the type of interaction between RpsA 
and POA we made use of several NMR techniques CSP, DOSY and STD being able to determine affinity from 
the order of nano, micro and millimolar, respectively, as previously demonstrated in previous studies evaluating 
interactions between PZA, POA and a variety of PZA analogs with fatty synthase I (FAS I) protein43. The NMR 
results showed that POA has a weak interaction for RpsA (in the mM range), an affinity that was unable to com-
pete against the strong binding to tmRNA, even at high POA concentrations.
The X-ray crystal structure of RpsA bound to POA, showing the interaction between POA and the RpsA S1 
domain, has been published12. The S1 domain was depicted using NMR spectroscopy 1H-15N HSQC12. However, 
experimental evaluation of the ligand-protein interaction was not shown. Moreover, in a subsequent paper, Fan 
and coauthors studied the interaction of the RpsA S1 domain with tmRNA using NMR39 and, surprisingly, the 
tmRNA-POA competition experiment was not addressed. The results we present here show low affinity of POA 
for RpsA at a level (mM) at which it is difficult to compete with the strong binding reported between RpsA and 
tmRNA (nM)11,39. The weak POA-RpsA interaction observed here by STD suggests that POA has co-crystallized 
with RpsA, possibly through a crystallization artifact generated by the high concentration crystallization 
conditions12.
Our experimental results are robust and consistent with each other across the different techniques used. They 
contrast with the results reported by Shi et al. (2011) and by Yang et al. (2015), which described a strong interac-
tion between RpsA WT and POA with an affinity constant of 7.53 × 106 M−1 and 3.56 × 105 M−1, respectively. 
Our data also confirm the findings obtained by Dillon et al. (2017) who also found no evidence of an interaction 
between RpsA and POA using ITC25.
Finally, in recent years there has been an attempt to relate mutations in RpsA to PZA resistance, based on the 
approaches discussed above. The sequencing of this gene has demonstrated mutations in both PZA-sensitive 
and -resistant strains. However, of the large number of RpsA mutations reported in strains susceptible to PZA 
(Q162R, D37A, K45E, L53V, A112T; I26L, I26V, E67V, G214V, N221H; K45Q, E197K, V254G, D268N, E405K, 
M432T) and resistant strains (R474W, R474L, E433D, K45N, I101T, Y164C, ∆Ala437, L138R, S151P, K167N, 
L185P, INSERT C193, E201G, R212W, K213Q, G214S, G229A, H244Q, R289L, S324P, V338A, G341S, INSERT 
G341, A376E, A412V, E413Q, D446A, S450T; R212R, M432T, F310F; K45E; V260I; DEL I26, V74I, K93R, 
L206L, K277R, S324F, E325K, G341R, D342N, A344P, I351F, T370P, W403G)44–49, very few have been found to 
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be consistently associated with resistance to PZA. Of note, strain DHM44450 with mutation ∆Ala438 is the only 
clinical strain reported to harbor this mutation on RpsA. This strain was described like “less susceptible to PZA, 
with a borderline or low-level resistance (MIC, 200 to 300 mg/mL, which is two to three times the MIC used to 
define susceptible strains)”51. Shi et al. generated the mutations ∆Ala438 and D123A in the MTB chromosome 
and confirmed PZA resistance (300 μg/mL)52.
It is important to emphasize that potential protein-protein interactions taking place in vivo between RpsA, 
SmpB, tmRNA and other compounds of trans-translation machinery may offer an explanation for the contradic-
tory results reported so far. More studies are needed to establish a model to determine how RpsA mutations are 
associated with resistance to PZA, as this relationship remains unclear53,54.
In conclusion, our experimental results present evidence that there is no interaction between RpsA WT and 
POA. We also show that the binding between MTB RpsA WT and tmRNA is not displaced by POA under the 
conditions applied in the present study. These findings suggest that RpsA may not be involved in the mechanism 
of action of PZA in MTB, as was previously thought.
Materials and Methods
Cloning, expression, and purification of RpsA. The rpsA wild type (rpsA WT) gene was amplified by 
PCR from MTB H37Rv strain DNA. Proteinase K digestion55, digestion with BamHI and XhoI, and ligation into 
a pET28a plasmid (Novagen) with an N-terminal His-tag and Kanamycin resistance gene were performed.
MTB rpsA ∆A438 complete gene, rpsA ∆A438_CUT1 (468 aa), rpsA ∆A438_CUT2 (454 aa), and rpsA 
∆A438_CUT3 (440 aa) (Fig. 1) were synthesized and cloned in a pET28a vector (Genemed Synthesis, Inc).
All recombinant proteins were expressed in E. coli BL21 (DE3). The cells were grown at 37 °C to an optical 
density (O.D) of 0.6–0.8, and expression was induced with 0.5 mM IPTG at 25 °C for 8 hours. The bacteria were 
centrifuged (15 min at 4 °C and 6 000 rpm) and the pellet resuspended in 20 mM Tris-HCl buffer, pH 8, 300 mM 
NaCl. Cells were disrupted by three freeze-thaw cycles, followed by three sonication cycles on ice (1 min active, 
1 min inactive). Debris was separated by centrifugation (13 000 rpm x 15 min), and the supernatant was recovered 
by a further centrifugation step (13 000 rpm x 15 min). Samples were treated with DNase and RNase to determine 
the type of nucleic acid associated with the purified protein. Treated samples were migrated in native PAGE on 
twin gels: one was stained with Coomasie blue and the other with ethidium bromide. Finally, all samples were 
processed with RNase A for 16 hours at 4 °C.
Purification was achieved by Ni2+ affinity chromatography56, using 10 mM to 500 mM Imidazole (linear gra-
dient). The purified fractions were concentrated by ultrafiltration using Amicon (Millipore) 10 KDa cutoff filters; 
they were washed repeatedly with phosphate-buffered saline (PBS) until all the imidazole had been removed. 
Protein concentration was determined by measuring absorbance at 280 nm (extinction coefficient: ε = 46410 M−1 
cm−1, estimated by the ExPASy ProtParam tool (http://web.expasy.org/protparam/))57. Additionally, in order to 
evaluate the presence of any remaining nucleic acids in the purified proteins, absorbance at 260 nm was measured, 
and twin gels (5% native polyacrylamide) were processed and stained with ethidium bromide and Coomassie 
blue.
Production of tmRNA. The ssrA gene was amplified from 10 ng MTB H37Rv genomic DNA using primers 
at 0.5 μM which included the T7 promoter sequence: Forward 5′-TAA TAC GAC TCA TCA TAG GAT CTG 
ACC GGG AAG TTA ATG GC-3′ and reverse 5′-GAT CAG ATC CGG ACG ATC GGC ATC G-3′11. Phusion 
flash PCR Master mix (Thermo scientific F-548L) was used with a final volume of 20 μL. Cycling parameters 
included 98 °C for 10 sec, 70 °C for 10 sec and 72 °C for 15 sec, ending with a cycle of 72 °C for 1 min. The 620 bp 
products were purified using the High Pure Clean-Up kit following the manufacturer’s instructions (Roche-life 
technologies).
From the amplified and purified product, in vitro transcription was performed using the TranscriptAid T7 
High Yield Transcription Kit as previously described11. Briefly, the transcription of 1 μg of DNA was carried out 
at 37 °C for 2 hours. Purification of the 602 bp product was performed using the Thermo scientific geneJET RNA 
purification kit, ranging from 2–6 μg/μL.
Electrophoretic Mobility Shift Assay (EMSA) to test the interaction between tmRNA and RpsA 
WT. tmRNA (10 pmol) was prepared as previously described11. RpsA WT (10 μM), 5% glycerol, 80 mM KCl, 
9 mM MgCl2, 100 μg/mL BSA, and 20 U RNasin were combined in a final volume of 20 μL and incubated at room 
temperature for 1 hour. Samples were mixed with 5 μL REMSA loading buffer 5× (Thermo Scientific) and ana-
lyzed by electrophoresis (5 mA for 4 hours) in 5% polyacrylamide gel at 0.5X TBE, then stained with ethidium 
bromide.
Microscale Thermophoresis (MST) to test the interaction between tmRNA and RpsA WT. RpsA 
was labeled using the MO-L008 Monolith His-tag Labeling kit RED-tris-NTA following the protocol available 
from the manufacturer (100 nM final concentration in PBS-T buffer). A 16-step dilution series was undertaken 
by adding 10 μL MST buffer with 0.1% Tween 20 to 15 tubes. Twenty μL of 4.1 μM tmRNA was placed in the first 
tube, and 10 μL was transferred to the second tube and mixed well by pipetting. This was repeated to generate a 
1:1 dilution series. 10 μL of RpsA was added to each tube (final concentration 50 nM). The samples were incu-
bated at room temperature for 15 minutes then loaded into Standard Monolith NT capillaries. The capillaries were 
scanned using a Monolith NT.115 MST instrument (medium MST power, 5% excitation power) and the data 
analyzed using MO Affinity Analysis software v2.2.4 (NanoTemper Technologies GmbH). The measured fluores-
cence was normalized and averaged, and the binding constant was determined using a global fit calculation and 
a 1:1 fitting model. A rough estimate of the affinity constant with its 95% confidence interval was obtained after 
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fitting the experimental data with the theoretical corresponding function (NanoTemper Technologies Software 
Analysis).
Electrophoretic Mobility Shift Assay (EMSA) to test the interaction between POA and RpsA var-
iants. The interaction between POA with RpsA WT, RpsA ∆A438, and the truncated variants of RpsA ∆A438 
was indirectly evaluated by measuring a change in the electrophoretic mobility of the tmRNA when bound to 
RpsA and the displacement of tmRNA after adding POA. The methodology was similar to that described above. 
POA (300 μg/mL) was used for the competition study with tmRNA. Under these conditions, the POA:tmRNA 
and POA:RpsA molar ratios were 5:1 and 25:1 respectively.
Isothermal Titration Calorimetry (ITC) to test the interaction between POA and RpsA vari-
ants. Binding affinity was measured at 25 °C by Isothermal Titration Calorimetry (ITC) using a VP-ITC 
instrument (Microcal Inc, Northhampton, MA). RpsA proteins (20 μM) were dialyzed and prepared in ITC buffer 
consisting of 10 mM phosphate buffer (Na2HPO4 – NaH2PO4), pH 6.0, and 150 mM NaCl. Protein concentrations 
were determined with a UV spectrometer using an extinction coefficient (ε) of 46410 M−1 cm−1. POA (550 μM, 
FLUKA Chemika) samples were prepared in the same ITC buffer, and ligand concentrations were determined 
by weight per volume. Ligand was injected 30 times (10 μL per injection during 12 s) into the cell containing the 
protein solution at intervals of 300 s. The stirring speed was 300 rpm. Feedback Mode/Gain was high and filter 
period was 2 s.
Binding parameters were determined from isotherms after subtracting the average heat of dilution 
(~ −0.2 kcal/mol) using the MicroCal Data Analysis software (Malvern, Westborough, MA). Experiments were 
conducted in duplicate for each protein.
Nuclear Magnetic Resonance spectroscopy (NMR) to test the interaction between POA and 
RpsA variants. POA stock solution (10 mM) was dissolved in 100 mM phosphate buffer containing150 mM 
NaCl. After carefully adjusting the pH to 6.4 it was lyophilized and resuspended in D2O. RpsA samples were 
buffer-exchanged with D2O buffer containing 100 mM phosphate, pH 6.4 and 150 mM NaCl using Zeba Spin 
Desalting Columns (7 K MWCO, 2 mL).
All NMR experiments were recorded at 25 °C on a Bruker Avance III HD 500 MHz spectrometer equipped 
with SMART probe. 1H-NMR experiments were acquired using the Watergate suppression technique to elimi-
nate residual solvent signal, with 384 scans, 64k data points, a spectral width of 10 kHz, and a total relaxation time 
of 6.28 s.
Diffusion Ordered Spectroscopy (DOSY) experiments were recorded using Watergate pulsed-field gradi-
ent stimulated echo (PFGSE) pulse sequence with a 500 ms diffusion delay, 300 µs bipolar gradients, gradient 
strengths of 2.17, 6.50, 10.84, 15.17, 19.50, 23.84, 28.17, 32.51, 36.84, 41.17 gauss/cm, 256 scans per gradient 
strength, 64k data points, a spectral width of 10 kHz, and a total relaxation time of 13.28 s. Translational diffusion 
coefficients were determined using a Stejskal–Tanner equation58.
Saturation Transfer Difference (STD) experiments were acquired using Watergate suppression. Selective pro-
tein saturation was achieved by applying a series of 1 ms low power (0.019727 Watts) Gaussian shaped pulses and 
a total saturation time of 6 s. ‘On’ resonance frequency was set at 0.84 ppm, and ‘off ’ resonance frequency at 100 
ppm35.
The flip angle was calibrated for each individual sample using 360° pulse optimization. Spectra were Fourier 
transformed with 0.3 Hz exponential apodization, and phase and baseline corrected using Topspin 3.5 pl5 
software.
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